English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Summary  Radioiodine ( 131 I) is a critical component in the treatment of differentiated thyroid cancer. We recently saw a patient with thyroid cancer who was hesitant to take  131 I treatment because he had previously encountered an allergic reaction to administration of iodine-containing radiocontrast agent for computed tomography (CT) scanning. We were able to administer  131 I treatment after discussion that his anaphylactic reaction was not due to iodine and that radioiodine ( 131 I) treatment is unlikely to cause a reaction in the patient.   Learning pointsAn allergy to iodine itself does not exist.    When patients claim that they have an ‘iodine allergy’, ask them what substances they are allergic to and what kind of reaction occurred during use of such substances.    Radioactive iodine is not a contraindication for patients who claim an ‘allergy to iodine’.

Radioiodine treatment of differentiated thyroid cancer despite history of ‘iodine allergy’